Chardan Capital Issues Optimistic Estimate for SLDB Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at Chardan Capital increased their FY2025 earnings estimates for Solid Biosciences in a research note issued to investors on Wednesday, February 19th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($1.82) per share for the year, up from their prior forecast of ($2.03). Chardan Capital currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

A number of other equities analysts have also recently commented on SLDB. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a report on Friday, January 10th. JPMorgan Chase & Co. reduced their target price on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Truist Financial started coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price target on the stock. JMP Securities started coverage on Solid Biosciences in a report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Citizens Jmp upgraded shares of Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Nine equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.40.

Solid Biosciences Price Performance

Solid Biosciences stock opened at $5.29 on Monday. The company’s 50-day moving average is $3.86 and its 200-day moving average is $5.71. The firm has a market capitalization of $214.66 million, a PE ratio of -1.74 and a beta of 2.01. Solid Biosciences has a fifty-two week low of $2.88 and a fifty-two week high of $15.05.

Insider Activity at Solid Biosciences

In other news, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $25,816.00. Following the transaction, the insider now directly owns 14,235 shares of the company’s stock, valued at approximately $79,716. This trade represents a 24.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Alexander Cumbo sold 11,114 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $62,238.40. Following the completion of the sale, the chief executive officer now owns 38,484 shares of the company’s stock, valued at approximately $215,510.40. This trade represents a 22.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,069 shares of company stock worth $137,301. Corporate insiders own 13.63% of the company’s stock.

Hedge Funds Weigh In On Solid Biosciences

A number of hedge funds have recently added to or reduced their stakes in SLDB. Wells Fargo & Company MN grew its holdings in shares of Solid Biosciences by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock worth $53,000 after purchasing an additional 2,986 shares in the last quarter. Rhumbline Advisers raised its position in shares of Solid Biosciences by 10.5% in the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company’s stock valued at $175,000 after buying an additional 4,161 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Solid Biosciences by 4.0% during the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company’s stock worth $498,000 after acquiring an additional 4,747 shares during the period. Geode Capital Management LLC boosted its position in shares of Solid Biosciences by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 509,802 shares of the company’s stock worth $2,040,000 after acquiring an additional 4,932 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Solid Biosciences by 12.3% during the fourth quarter. American Century Companies Inc. now owns 46,857 shares of the company’s stock valued at $187,000 after purchasing an additional 5,126 shares in the last quarter. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.